Antiretroviral News and Research

RSS

UC San Diego chosen to lead an international $28-million grant for HIV/AIDS clinical trials

University of California San Diego Collaborative Clinical Trials Unit has been selected by the National Institutes of Health to lead and administer an international seven-year, $28-million grant for science-driven clinical trials that deliver innovative, efficient results needed to turn the corner on the HIV/AIDS pandemic.

30 Nov 2020

IPM announces WHO's prequalification of dapivirine ring to reduce women’s HIV risk

The nonprofit International Partnership for Microbicides is pleased to announce the World Health Organization's prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.

30 Nov 2020

HIV alters SARS-CoV-2 immune response without affecting COVID-19 symptoms or outcomes

In a preprint paper published on the medRxiv server, a team of researchers from various institutions in South Africa, the UK, and Europe discuss how they determined the impact of HIV on the COVID-19 immune response in KwaZulu-Natal, South Africa, which is an area with very high HIV prevalence.

26 Nov 2020

Largest clinical trial launched to treat mild-to-moderate COVID-19 patients in Africa

Thirteen African countries and an international network of research institutions have joined forces to launch the largest COVID-19 clinical trial in mild-to-moderate outpatients in Africa.

24 Nov 2020

Discovery of 'Achilles heel' in protein crucial to HIV virulence could lead to new class of drugs

The discovery of a potential "Achilles heel" in Nef, the protein that is crucial to HIV virulence and its capacity to trigger AIDS, paves the way for the development of a new class of drugs against the virus.

17 Nov 2020

Cabotegravir highly effective in preventing HIV among women

UNAIDS has been strongly encouraged by groundbreaking new study results showing that the antiretroviral medicine cabotegravir administered by an injection every two months – prevents HIV among women.

10 Nov 2020

Trial results show CAB LA is more effective in preventing HIV acquisition in women

The HIV Prevention Trials Network study (HPTN 084) on the safety and efficacy of the long-acting injectable antiretroviral drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected women, was stopped early by the trial Data and Safety Monitoring Board (DSMB) as results showed CAB LA to be highly effective in preventing HIV acquisition.

10 Nov 2020

Study identifies new cause of inflammation in people living with HIV

While current antiretroviral treatments for HIV are highly effective, data has shown that people living with HIV appear to experience accelerated aging and have shorter lifespans - by up to five to 10 years - compared to people without HIV.

30 Oct 2020

Study: Toxins produced by tube-dwelling anemones have pharmacological potential

Researchers based in Brazil and the United States have completed the first-ever mapping exercise to profile the toxins produced by tube-dwelling anemones, or cerianthids, a family of marine animals belonging to the same phylum (Cnidaria) as sea anemones, jellyfish and corals.

30 Oct 2020

Study: Antiretroviral therapy fails to restore age-appropriate epigenetic patterns

Untreated HIV infection is linked with epigenetic changes that suggest rapid aging. A new study by UCLA researchers shows that antiretroviral therapy given over two years was unable to completely restore age-appropriate epigenetic patterns, leaving patients more susceptible to aging-related illnesses.

22 Oct 2020

NIH awards $1.6 million for research on hormonal control of HIV latency

The National Institutes of Health has awarded $1.6 million to researchers at the George Washington University School of Medicine and Health Sciences for research on hormonal control of HIV latency.

20 Oct 2020

Researchers explore new method to monitor the effectiveness of HIV treatment at home

Development of a new method to monitor the effectiveness of human immunodeficiency virus (HIV) treatment at home instead of in hospitals is underway by Penn State researchers.

20 Oct 2020

Dolutegravir is a first-line treatment for people newly diagnosed with HIV

A new study by UBC researchers is set to change international treatment recommendations for people who are newly diagnosed with HIV--an update that could affect nearly two million people per year worldwide.

19 Oct 2020

Glutathione precursor improves multiple deficits associated with premature aging

Premature aging in people with HIV is now recognized as a new, significant public health challenge. Accumulating evidence shows that people with HIV who are between 45 to 60 years old develop characteristics typically observed in people without HIV that are more than 70 years of age.

15 Oct 2020

HIV self-tests improve "door-to-door" testing campaigns

Despite significant progress in prevention and therapy, millions of people still get infected with HIV every year.

12 Oct 2020

Researchers develop international policy index for HIV prevention among drug users

Peter Meylakhs, from HSE University - St. Petersburg, together with colleagues from Georgia State University (USA) and Tarbiat Modares University (Tehran), have developed the HIV-PWID Policy Index (HPPI)--an international policy index for HIV prevention among people who inject drugs.

9 Oct 2020

Study determines frequency and patterns of T-cell escape mutations in HIV patients undergoing antiretroviral therapy

Immune cells that can recognize residual HIV-infected cells in people living with HIV (PLWH) who take antiretroviral therapy (ART) remain active for years, says a new study published today in eLife.

7 Oct 2020

Study shows why antiretroviral therapy does not work in certain HIV patients

Increasingly, UPMC's chief of infectious diseases-;a well-regarded expert in HIV/AIDS-;is contacted by a perplexed physician describing a patient with HIV who insists they are adhering to the daily medication regimen meant to keep the virus in check, but testing says otherwise.

6 Oct 2020

The implications of COVID-related sexual distancing and clinical service interruption

A recent study conducted in the Atlanta area reveals that coronavirus disease 2019 (COVID-19) related sexual distancing together with clinical service interruption for sexually transmitted diseases can potentially impact the future incidence of human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs). The study is currently available on the medRxiv* preprint server.

4 Oct 2020

A detailed map of latent virus reservoir in individuals with HIV

The latent reservoir is the last bastion of HIV's resistance to a cure. But it is difficult to destroy because it is invisible: the cells in the reservoir harbor virus that is dormant, so they don't have any viral proteins on their surface that would give them away.

30 Sep 2020